Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
What is hepatitis C?
Hepatitis C is an infection caused by a virus called HCV. It travels in the blood and settles in the liver, where it causes inflammation. Most people feel nothing for years, which is why so many never find out they have it. The CDC estimates 2.4 to 4 million people in the US had hepatitis C during 2017 to 2020, and most didn't know it. In 2023, doctors reported 4,966 new acute cases, but the CDC believes the real number was closer to 69,000. More than half of infected people never clear the virus on their own, and the infection becomes long term.
A few things make hepatitis C research unusual. There are 7 known strains of the virus, and modern antivirals work against all of them. In trials, "cure" has a strict meaning: no virus in the blood 12 weeks after treatment ends, called SVR12. Since a cure already exists, new drugs get tested against approved treatments instead of a placebo. In July 2026, a new two drug combination cleared that bar in a large late stage study. Most other studies here aren't drug trials at all. They focus on reaching people the cure has missed, through pharmacies, prisons, pregnancy care, and telemedicine.
Is hepatitis C curable?
Yes. A course of antiviral pills taken for 8 to 12 weeks cures more than 95 out of 100 people, whichever strain of the virus they carry. Cure means the virus can no longer be found in your blood, and it does not come back on its own. The hard part is not the cure anymore, it is finding the people who need it, since most people with hepatitis C have no symptoms and never get tested. That is what most studies on this page are working on.
What is the difference between hepatitis A, B, and C?
They are three different viruses that all inflame the liver, and the symptoms look alike. What differs is how you catch them and what medicine can do. Hepatitis A is swallowed, through close contact or contaminated food or drink, and it is usually a short illness people recover from completely, with no long term form. Hepatitis B spreads through blood, semen, and some other body fluids, and can turn long term, and the medicines for it are not a cure. Hepatitis C spreads through blood and is the one that can be cured with pills. The other split is prevention: vaccines exist for hepatitis A and hepatitis B, but not for hepatitis C.
Types of Hepatitis C clinical trial
Hepatitis C research can be undertaken using various types of clinical trials, each serving distinct purposes in the development and evaluation of treatments for the virus. Depending on the objectives of the trial, researchers may choose any one of the following commonly used trial types for Hepatitis C.
Interventional trials
Interventional trials are often used by researchers seeking to advance Hepatitis C treatment by actively testing new antiviral drugs, combination therapies, optimal dosing, and treatment durations to improve efficacy and minimize side effects. These trials often involve randomization, control groups, and blinding to ensure unbiased results, with primary endpoints like sustained virologic response (SVR).
These types of trials can also assess treatments in specific populations, study viral resistance, and evaluate real-world effectiveness and prevention measures. By optimizing protocols and contributing to personalized medicine, interventional trials significantly enhance patient outcomes and reduce the public health burden of Hepatitis C.
Observational studies
Observational studies in Hepatitis C research involve monitoring and collecting data on patients without intervening, to understand the natural history of the disease, treatment outcomes, and associated risk factors. These studies include cohort studies that follow patients over time to observe disease progression and treatment effects and case-control studies that compare Hepatitis C patients with those without the infection to identify factors influencing disease development and outcomes.
In observational studies, researchers can provide valuable real-world evidence on long-term treatment efficacy, safety, and quality of life, informing clinical guidelines and improving patient management.
Adaptive trials
Adaptive trials in Hepatitis C clinical research are designed to allow modifications to the trial procedures based on interim results, enhancing flexibility and efficiency. These trials can adjust dosages, treatment durations, or even patient selection criteria in response to early findings, improving the likelihood of identifying effective treatments more quickly.
Studies using adaptive designs can also terminate ineffective treatments early, protecting participants from unnecessary exposure to ineffective therapies and focusing resources on promising options. By incorporating real-time data analysis, adaptive trials optimize the research process, making the development of new Hepatitis C treatments more responsive and adaptable.
Who can participate in hepatitis C clinical trials?
It depends on the type of study. Drug trials usually sort people by how far the liver disease has gone. Some enroll only people without cirrhosis, some look for people whose first treatment did not clear the virus, and some ask which strain of the virus you carry. Many current studies are not drug trials at all. They test better ways to find infected people and get them treated, in pharmacies, through telemedicine, during pregnancy, or in jails and prisons. There is also transplant research, where organs from donors who had hepatitis C go to patients who then get antivirals. These studies actively recruit groups older research left out, especially people who inject drugs, who also have high rates of HIV coinfection. Eligibility always varies by study.
Considering volunteering in a clinical trial? Explore our comprehensive guide to learn more about why people choose to volunteer and the impact you can make in advancing medical research. Discover the process of volunteering, what to consider before applying and the potential benefits and risks involved.
How to enroll in a Hepatitis C clinical trial
Enrolling in a clinical trial studying Hepatitis C through our platform is a straightforward and user-friendly process. Here's how to get started:
- Identify Your Trial: Use our intuitive search bar or filter options to locate clinical trials specific to requirements. This first step simplifies the process of finding relevant research studies tailored to your needs.
- Select Your Preferred Location: To find trials conveniently located near you, simply input your preferred location into the dedicated filter bar on the left-hand side of the page.
- Explore Study Details: For in-depth information about each study, simply click the “Learn More” button. This will provide you with comprehensive details about the trial, including objectives, procedures, and eligibility criteria.
- Complete the Health Profile: After clicking on the “Get started” button you will be taken to our efficient 5-step application process to provide important health information. This helps us match you with the clinical trial that best fits your needs.
- Submit the Application: After completing the application, send it in. A clinical trial coordinator will review it and contact you regarding the possibility of participation.